


## Testing Taskforce: New California COVID-19 cases, hospitalizations and deaths

### 14 day average Hospitalizations










Average test positivity past 7 days 5.4%, up 0.8% from last week Cases remain at relatively low levels 14 day average hospitalizations have declined to previous lows. 7 day average deaths remain at low levels.

## Wastewater data






COVID-19 cases are low in many countries around the world. There has been a rise and fall in cases in India and Singapore coinciding with an increasing prevalence of XBB.1.16 In the US cases are staying steady and relatively low.

## Daily new confirmed COVID-19 deaths per million people



7-day rolling average. Due to varying protocols and challenges in the attribution of the cause of death, the number of confirmed deaths may not accurately represent the true number of deaths caused by COVID-19.



Source: WHO COVID-19 Dashboard CC BY

Jan 8, 2020


# Variant Update: CDC Nowcast Estimate

### Weighted and Nowcast Estimates in United States for Weeks of 1/15/2023 – 4/22/2023

Nowcast Estimates in United States for 4/16/2023 – 4/22/2023



Hover over (or tap in mobile) any lineage of interest to see the amount of uncertainty in that lineage's estimate.



### USA US Class %Total WHO label Lineage # Omicron XBB.1.5 VOC 73.6% 69.6-77.3% XBB.1.16 VOC 9.6% 6.7-13.6% +3.9% VOC 7.9% XBB.1.9.1 6.1-10.1% +1.5% VOC XBB.1.9.2 2.1-4.0% +0.7% XBB.1.5.1 VOC 2.2% 1.7-2.8% 0.0% VOC 0.0% FD.2 1.6% 0.7-3.2% XBB VOC 1.0% 0.0% 0.6-1.8% BQ.1.1 VOC 0.7% 0.4-1.1% -0.3% CH.1.1 VOC 0.4% 0.2-0.5% 0.0% BQ.1 VOC 0.1% 0.0-0.1% 0.0% BN.1 VOC 0.0% 0.0-0.0% BA.5 VOC 0.0% 0.0-0.0% BA.2.75 VOC 0.0% 0.0-0.0% BA.2 VOC 0.0% 0.0-0.0% BF.7 VOC 0.0% 0.0-0.0% BA.2.75.2 VOC 0.0% 0.0-0.0% BA.5.2.6 VOC 0.0% 0.0-0.0% BF.11 VOC 0.0% 0.0-0.0% BA.4.6 VOC 0.0% 0.0-0.0% Other Other\* 0.1% 0.0-0.1%

- XBB.1.5 continues to decline as XBB.1.16 increases
- Small increases in XBB.1.9 sublineages as well

## XBB.1.16

- WHO variant under monitoring as of March 30th
- Lineage has rapidly increased in India followed by other Countries. Now rising in the US
- Leading countries (India and Singapore) are showing spike in cases

### Compared to XBB.1.5

- XBB.1.16 has two S protein substitutions: E180V and T478R
- Relative effective reproduction number is ~1.2 fold greater
- Paxlovid still works
- Lineage not tracked by CDC yet on nowcast

# Other Lineages to watch

- XBB.1.5.1 Growing slightly in the US
- XBB.1.9.1 Seen in Europe for some time. Growing slightly in the US

# Paxlovid Resistance Currently Not Seen

 Currently we are NOT seeing signs of mutations in SARS-CoV-2 likely to impact the effectiveness of Paxlovid

 We are monitoring the genomic sequencing data for known Paxlovid resistance mutations

Figure 1. Percentage of Influenza Detections at Clinical Sentinel Laboratories, 2017-2023 Season to Date




Figure 13. Percentage of RSV Detections at Clinical Sentinel Laboratories, 2017–2023 Season to Date

